These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15307009)

  • 21. Fibrosis Progression in Paired Liver Biopsies from HIV/HCV-Coinfected Patients without Prior Treatment of Hepatitis C.
    Leite AG; Duarte MI; Mendes-Correa MC
    J Int Assoc Provid AIDS Care; 2015; 14(5):463-8. PubMed ID: 26056147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes of first antiretroviral regimen in HIV/hepatitis C virus co-infection.
    Cooper CL; Breau C; Laroche A; Lee C; Garber G
    HIV Med; 2006 Jan; 7(1):32-7. PubMed ID: 16313290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.
    Crane HM; Van Rompaey SE; Kitahata MM
    AIDS Patient Care STDS; 2007 Dec; 21(12):920-9. PubMed ID: 18154489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis.
    Akhtar MA; Mathieson K; Arey B; Post J; Prevette R; Hillier A; Patel P; Ram LJ; Van Thiel DH; Nadir A
    Eur J Gastroenterol Hepatol; 2008 Dec; 20(12):1194-204. PubMed ID: 18989143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons.
    Mehta SH; Moore RD; Thomas DL; Chaisson RE; Sulkowski MS
    J Acquir Immune Defic Syndr; 2003 Aug; 33(5):577-84. PubMed ID: 12902801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade.
    Sauleda S; Martorell M; Esteban JI; Tural C; Ruiz I; Puig L; Esteban R; Guardia J; Vargas V
    Haemophilia; 2006 May; 12(3):228-36. PubMed ID: 16643206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations between lipodystrophy or antiretroviral medications and cirrhosis in patients with HIV infection or HIV/HCV coinfection.
    Ioannou GN; Bryson CL; Weiss NS; Boyko EJ
    Eur J Gastroenterol Hepatol; 2015 May; 27(5):577-84. PubMed ID: 25769096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
    Wit FW; Weverling GJ; Weel J; Jurriaans S; Lange JM
    J Infect Dis; 2002 Jul; 186(1):23-31. PubMed ID: 12089658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir.
    Palacios R; Vergara S; Rivero A; Aguilar I; Macías J; Camacho A; Lozano F; García-Lázaro M; Pineda JA; Torre-Cisneros J; Márquez M; Santos J
    HIV Clin Trials; 2006; 7(6):319-23. PubMed ID: 17197379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients.
    Stone SF; Lee S; Keane NM; Price P; French MA
    J Infect Dis; 2002 Nov; 186(10):1498-502. PubMed ID: 12404169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfection.
    Sterling RK; Wilson MS; Sanyal AJ; Luketic VA; Stravitz RT; Contos MJ; Mills AS; Shiffman ML
    Clin Gastroenterol Hepatol; 2004 May; 2(5):432-9. PubMed ID: 15118983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Livolin ameliorates elevations in alanine transaminase in HIV infected patients commencing highly active antiretroviral therapy.
    Otegbayo JA; Kuti MA; Ogunbode O; Irabor AE; Adewoles IF
    Afr J Med Med Sci; 2012 Dec; 41(4):417-22. PubMed ID: 23672107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.
    Qurishi N; Kreuzberg C; Lüchters G; Effenberger W; Kupfer B; Sauerbruch T; Rockstroh JK; Spengler U
    Lancet; 2003 Nov; 362(9397):1708-13. PubMed ID: 14643119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.
    Loko MA; Bani-Sadr F; Winnock M; Lacombe K; Carrieri P; Neau D; Morlat P; Serfaty L; Dabis F; Salmon D;
    J Viral Hepat; 2011 Jul; 18(7):e307-14. PubMed ID: 21692942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
    Law WP; Dore GJ; Duncombe CJ; Mahanontharit A; Boyd MA; Ruxrungtham K; Lange JM; Phanuphak P; Cooper DA
    AIDS; 2003 Oct; 17(15):2191-9. PubMed ID: 14523276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection.
    Mehta SH; Thomas DL; Torbenson M; Brinkley S; Mirel L; Chaisson RE; Moore RD; Sulkowski MS
    Hepatology; 2005 Jan; 41(1):123-31. PubMed ID: 15619237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection.
    Kovari H; Ledergerber B; Battegay M; Rauch A; Hirschel B; Foguena AK; Vernazza P; Bernasconi E; Mueller NJ; Weber R
    Clin Infect Dis; 2010 Feb; 50(4):502-11. PubMed ID: 20085465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute liver enzyme elevations in HIV-1-infected patients.
    Livry C; Binquet C; Sgro C; Froidure M; Duong M; Buisson M; Grappin M; Quantin C; Portier H; Chavanet P; Piroth L
    HIV Clin Trials; 2003; 4(6):400-10. PubMed ID: 14628283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
    Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
    J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.